Aegros Revenue and Competitors
Estimated Revenue & Valuation
- Aegros's estimated annual revenue is currently $25M per year.
- Aegros's estimated revenue per employee is $155,000
Employee Data
- Aegros has 161 Employees.
- Aegros grew their employee count by 55% last year.
Aegros Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $376.5M | 2429 | 9% | N/A | N/A |
#2 | $1.1M | 7 | -22% | N/A | N/A |
#3 | $7.5M | 61 | 20% | $106.1M | N/A |
#4 | $11.3M | 73 | N/A | N/A | N/A |
#5 | $18.6M | 120 | 33% | N/A | N/A |
#6 | $20.3M | 131 | 7% | N/A | N/A |
#7 | $1.7M | 11 | -72% | N/A | N/A |
#8 | $69.3M | 447 | 37% | N/A | N/A |
#9 | $28.7M | 185 | 5% | N/A | N/A |
#10 | $25M | 161 | 55% | N/A | N/A |
What Is Aegros?
At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the patient first through innovation and we do thanks to the Australian invented HaemaFrac®, Aegros' unique electroseparation process. Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. Aegros is currently undertaking the final precommercial phase of a clinical trial of our Covid-19 hyperimmune in conjunction with a major Sydney hospital.
keywords:N/A
N/A
Total Funding
161
Number of Employees
$25M
Revenue (est)
55%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Macquarie Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $58.3M | 163 | -5% | N/A |
#2 | $45M | 163 | 4% | N/A |
#3 | $55.2M | 186 | -13% | N/A |
#4 | $31.2M | 218 | -54% | $95.6M |
#5 | $35.9M | 225 | -5% | N/A |